FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.
The biggest rounds of recent biotech financings are from startups raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Abdera Therapeutics, Complement Therapeutics, and Enveda Biosciences.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Three months after Alentis Therapeutics’ lead program posted positive Phase 1 data, the biotech has raised cash to advance that program to mid-stage testing in fibrosis. The Series C financing will also support a cancer drug candidate ready to start human testing.
Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.
Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.
Roche will provide $390 million in cash upfront and then provide milestone payments to acquire Promedior, which is developing a drug to treat a rare and fatal lung disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
Firm raises funding for RNAi therapy's clinical development from group of Chinese funds.
Biopharma vet Deborah Dunsire has joined Waltham, Massachusetts-based XTuit Pharmaceuticals, a startup targeting the microenvironments that protect and drive certain cancers and fibrotic diseases.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It plans to bring its idiopathic pulmonary fibrosis small molecule to the clinic in the next two years.
VP Donnie McGrath said at this week's RESI conference in Houston that Bristol-Myers Squibb is targeting heart failure, virology, immunoscience, rare disease and fibrosis.